Asia, Europe, Middle East, And Africa Anal Fissure & Hemorrhoids Treatment Market Research Report Forecast to 2030

Description

Asia, Europe, Middle East, And Africa Anal Fissure & Hemorrhoids Treatment Market Research Report Forecast to 2030

Market Overview

The Asia, Europe, Middle East, and Africa anal fissure & hemorrhoids treatment market is expected to be driven by the increasing incidence of hemorrhoids and anal fissures, rising adoption of sedentary lifestyles, unhealthy eating habits, and increasing prevalence of constipation. However, the presence of alternative treatment therapies and lack of awareness and the feeling of embarrassment are likely restraining factors for market growth. Additionally, players entering untapped markets is expected to create lucrative growth opportunities for the Asia, Europe, Middle East, and Africa anal fissure and hemorrhoids treatment market.

An anal fissure is a linear tear in the mucosal lining of the distal anal canal below the dentate line. On the other end, the hemorrhoid is a condition wherein the veins get swollen up in the anal canal. It is known as piles. Hemorrhoids and anal fissures cause similar symptoms, such as itching, pain, and bleeding. While swollen veins cause hemorrhoids, a tear in the lining of the anus causes an anal fissure. The increasing incidence of hemorrhoids and anal fissures significantly propelled the market growth. Additionally, rising adoption of sedentary lifestyles and unhealthy eating habits

Market Segmentation

Anal fissures are tears of the sensitive mucosal lining of the anus. It is also known as an anal ulcer. It causes severe pain and bleeding during bowel movements. Hemorrhoids are a condition wherein the veins get swollen up in the anal canal. Most of the population under the age of 50 is suffering from Hemorrhoids but does not realize it until it turns into excessive pain and irritation.

The Asia, Europe, Middle East, and Africa anal fissure and Hemorrhoids treatment system market, by route of administration, is bifurcated into oral, topical, and others. The topical segment held the largest market share in Asia, Europe, Middle East, and Africa anal fissure and hemorrhoids treatment market by route of administration in 2021.

Asia, Europe, Middle East, and Africa anal fissure and hemorrhoids treatment system market, by distribution channel, is bifurcated into retail pharmacies, e-commerce, and others. The retail pharmacies segment held the largest market share in the Asia, Europe, Middle East, and Africa anal fissure and hemorrhoids treatment market by distribution channel in 2022.

By end-user, Asia, Europe, Middle East, and Africa anal fissure and hemorrhoids treatment system market is bifurcated into hospitals and clinics, ambulatory surgical centers (ASCs), and others. The hospitals & clinics segment held the largest market share in the Asia, Europe, Middle East, and Africa anal fissure and hemorrhoids treatment market by end user in 2021.

The anal fissure & hemorrhoids treatment market is studied across Europe, Asia-Pacific, and the Middle East & Africa. Europe showed the highest market revenue of USD 1,427.11 million in 2021.

Major Players

The key players operated in the market are Abbott Laboratories (US), Bayer AG (Germany), Boston Scientific Corporation (US), AbbVie Inc. (US), Kyowa Kirin International plc (UK), Medtronic Plc (Ireland), Troikaa Pharmaceuticals Ltd. (India), Taj Pharmaceuticals Limited (India).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING INCIDENCE OF HEMORRHOIDS AND ANAL FISSURES
4.2.2 RISING ADOPTION OF SEDENTARY LIFESTYLES AND UNHEALTHY EATING HABITS
4.2.3 INCREASING PREVALENCE OF CONSTIPATION
4.3 RESTRAINTS
4.3.1 ALTERNATE TREATMENT THERAPIES
4.3.2 SOCIAL STIGMA AND LACK OF AWARENESS
4.4 OPPORTUNITIES
4.4.1 ENTERING UNTAPPED MARKETS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 ENGAGEMENT & DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES FOLLOW-UPS
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE MARKET
6 ASIA, EUROPE, MIDDLE EAST, AND AFRICA ANAL FISSURE & HEMORRHOIDS TREATMENT MARKET, BY TREATMENT TYPE
6.1 INTRODUCTION
6.2 ANAL FISSURE
6.2.1 MEDICATION
6.2.1.1 TOPICAL NITROLGYLECRIN
6.2.1.2 CALCIUM CHANNEL BLOCKERS
6.2.1.3 STOOL SOFTENERS
6.2.1.4 OTHERS
6.2.2 SURGERY
6.3 HEMORRHOIDS
6.3.1 MEDICATION
6.3.2 SURGERY
7 ASIA, EUROPE, MIDDLE EAST, AND AFRICA ANAL FISSURE & HEMORRHOIDS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1 INTRODUCTION
7.2 ORAL
7.3 TOPICAL
7.4 OTHERS
8 ASIA, EUROPE, MIDDLE EAST, AND AFRICA ANAL FISSURE & HEMORRHOIDS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
8.1 INTRODUCTION
8.2 RETAIL PHARMACIES
8.3 E-COMMERCE
8.4 OTHERS
9 ASIA, EUROPE, MIDDLE EAST, AND AFRICA ANAL FISSURE & HEMORRHOIDS TREATMENT MARKET, BY END-USER
9.1 INTRODUCTION
9.2 HOSPITALS & CLINICS
9.3 AMBULATORY SURGICAL CENTERS (ASCS)
9.4 OTHERS
10 ASIA, EUROPE, MIDDLE EAST, AND AFRICA ANAL FISSURE & HEMORRHOIDS TREATMENT MARKET, BY REGION
10.1 INTRODUCTION
10.2 EUROPE
10.2.1 GERMANY
10.2.2 FRANCE
10.2.3 UK
10.2.4 ITALY
10.2.5 SPAIN
10.2.6 AUSTRIA
10.2.7 REST OF EUROPE
10.3 ASIA
10.3.1 JAPAN
10.3.2 CHINA
10.3.3 INDIA
10.3.4 REST OF ASIA
10.4 MIDDLE EAST & AFRICA
10.4.1 SAUDI ARABIA
10.4.2 UNITED ARAB EMIRATES
10.4.3 QATAR
10.4.4 AFRICA
10.4.5 REST OF MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN THE ASIA, EUROPE, MIDDLE EAST & AFRICA ANAL FISSURE AND HAEMORRHOIDS TREATMENT MARKET
11.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE MARKET
11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.5.1 MERGER & ACQUISITIONS
11.6 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO
11.6.1 SALES (USD MILLION), 2020
11.6.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2020
12 COMPANY PROFILES
12.1 ABBOTT LABORATORIES
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 BAYER AG
12.2.1 COMPANY OVERVIEWS
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 COOK MEDICAL
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIES
12.4 TROIKAA PHARMACEUTICALS LTD
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS/SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIES
12.5 TAJ PHARMACEUTICALS LIMITED
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS/SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIES
12.6 ABBVIE INC
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 KYOWA KIRIN INTERNATIONAL PLC
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 INTEGRA LIFESCIENCES CORPORATION
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 BOSTON SCIENTIFIC CORPORATION
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 MEDTRONIC PLC
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.10.6 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS